Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
April 24, 2015
Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 … [Read More...]
April 19, 2015
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor … [Read More...]